National Lipid Association Releases Results of Survey on Barriers to PCSK9 Inhibitor Prescription Approval Process

Image:

Body:

The National Lipid Association (NLA) released on Wednesday the results of its survey on the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor prescription approval process.

Category:

Front Page

Dates:

Wednesday, May 24, 2017 to Wednesday, August 16, 2017

Link the Feature to::

https://www.lipid.org/nla/national-lipid-association-releases-results-survey-barriers-pcsk9-inhibitor-prescription

This page was last updated: Jun 25, 2019

To enhance the science and practice of lipidology and promote optimal cardiometabolic health.

new_about

new_practice

new_meetings

new_membership

new_communications

National Lipid Association Releases Results of Survey on Barriers to PCSK9 Inhibitor Prescription Approval Process

Search form

To enhance the science and practice of lipidology and promote optimal cardiometabolic health.

new_about

new_practice

new_meetings

new_membership

new_communications

National Lipid Association Releases Results of Survey on Barriers to PCSK9 Inhibitor Prescription Approval Process